Hyaluronic Acid in Belem Brazil
Injectable fillers are one of the most popular facial rejuvenation techniques. As we age, the underlying tissues that keep our skin looking youthful and firm begin to break down due to the effects of gravity, sun exposure, diet, genetic factors, and years of facial muscle movement. Over time these factors contribute to the development of lines, wrinkles, and folds in the face.
Your skin consists of two layers known as the epidermis and the dermis. The epidermis, or outer layer of the skin, acts as the skin’s primary defense against the environment. The dermis, or innermost layer of the skin, is composed primarily of connective tissue and provides the skin with a support network. Most facial wrinkles and deeper folds occur within the dermal layer of the skin.
Within the connective tissue of the dermis, collagen and elastin fibers form a network that provides the skin with structure, support, and elasticity. Furthermore, fat cells and other molecules, such as hyaluronic acid, help to create volume beneath facial skin. With time, this network of collagen and elastin fibers breaks down, and hyaluronic acid molecules and fat cells that create volume are depleted. Together breakdown and depletion of these molecules result in wrinkles and other changes to facial skin.
When used as standalone treatments or with other procedures, injectable fillers can reduce or eliminate wrinkles and scars, create fuller lips, and treat lipoatrophy, or fat loss beneath the skin. With little downtime and almost immediate results, injectable fillers offer a safe, effective method of restoring a smoother, more youthful appearance.
Hyaluronic acid is a naturally occurring complex sugar molecule that forms large matrices in the connective tissue of the body, such as skin and cartilage. Much like a sponge, its primary function is to bind and absorb water molecules, which creates volume in the face. Hyaluronic acid fillers are generally used to treat facial wrinkles and folds and to enhance the appearance of the lips. One of the fastest growing dermal filler treatments available, hyaluronic acid fillers work by replacing the hyaluronic acid in the body that has depleted over time, which restores the volume beneath the skin’s surface.
While there are a variety of hyaluronic acid fillers, some of the most common are Hylaform®, Restylane®, and Juvederm®. Hylaform®, marketed by INAMED Aesthetics, consists of avian, or bird-derived, hyaluronic acid. Restylane®, marketed by Medicis, and Juvederm®, marketed by Allergan, are both non-animal derived forms of hyaluronic acid produced in the laboratory. Hyaluronic acid fillers are generally biocompatible, which means allergy skin testing is not required prior to treatment.
Depending on the extent of treatment, hyaluronic acid injection procedures typically last between fifteen and sixty minutes. Prior to the start of your procedure, the treatment areas will be cleansed, usually using an alcohol based cleaner. Unlike collagen injections, hyaluronic acid injections do not include an anesthetic agent. Therefore, a local or topical anesthetic may be used to numb the treatment area during the procedure.
Using an ultra fine needle, hyaluronic acid is injected into the dermis at several points along the edge of the treatment area. After approximately two to three injections, the physician will massage the treatment area. The physician will continue injecting the filler along the length of the wrinkle or fold until maximum correction has been achieved. If a local anesthesia has not been used, you may feel some minor stinging from the injections. As the injected hyaluronic acid molecules attract and bind water molecules, the volume beneath the skin will increase, restoring a smoother, more youthful appearance.
Immediately following the injections, you may experience some redness, slight stinging, minor swelling, or bruising in the treatment area. Tiny scabs may also form at the injection sites. These symptoms typically disappear within two to three days. No bandaging is necessary and most patients are able to resume normal activities immediately.
The body will eventually metabolize and absorb the injected hyaluronic acid over time. Therefore, while the effects are immediate, hyaluronic acid injections do not provide the same long-lasting results that may be gained from cosmetic surgery. Although the longevity of results varies by patient, results from hyaluronic acid injections are typically maintained for six to twelve months.
More Belem info...
Belem Get around
A good, cheap bus system serves most of the city, but it can be confusing at first. Be sure to ask the driver before getting on to make sure it's going to your destination. There is a direct bus to and from the airport that passes through most of the major tourist areas. Leaving the terminal turn left and walk past the end of the airport to the roundabout. The bus stop there will take you directly into town.
-
Belem Get in
It is possible to travel by air-conditioned coach to Bel?m from most major points in Brazil. However, due to its relative isolation, travel times can be quite lengthy - especially from the south. Flying is the most practical alternative. There are two regular international flights linking Bel?m to Cayenne in the French Guiana and Miami in USA; however there are many direct domestic flights linking Bel?m to Brasilia, Fortaleza, Manaus, Rio de Janeiro and Macap?.
-
Plastic Surgery News...
- On April 3 and 4, the National Academy of Sciences will hold a meeting to identify and promote practical interventions that could better link knowledge with action in pursuit of sustainable development. Presenters will summarize and discuss relevant research and practical experience from around the world.
- According to PharmaLive, the FDA has approved abatacept (Orencia®) for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients aged six years and above. It may be used as monotherapy or concomitantly with methotrexate (MTX), but should not be used concomitantly with tumour necrosis factor (TNF) antagonists or other biological therapy (e.g. anakinra).
This approval is based on the AWAKEN trial, which included 190 patients aged 6-17 years with moderately to severely active polyarticular JIA who had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). The first part was a 4-month, open-label lead-in phase in which patients received IV abatacept (10 mg/kg; maximum 1,000 mg) on Days 1, 15, 29 and every month thereafter. Those who achieved an ACR Pedi 30 response entered Period B - a six-month, double-blind phase involving randomisation to remain on abatacept (n=60) or to receive placebo (n=62) for six months. The primary endpoint of the study was time to occurrence of disease flare.
The main findings were as follows:
• In the lead-in phase, abatacept treatment resulted in a consistent improvement in ACR Pedi 30 across all JIA subtypes (oligoarticular extended - 59.3%; polyarticular-RF positive - 68.4%; polyarticular-RF negative - 64.3%; and systemic JIA with polyarticular course - 64.9%)
• The time to occurrence of disease flare was statistically significantly longer in patients treated with abatacept compared to patients treated with placebo compared with abatacept (p=0.0002) [no specific details given on magnitude of this difference]
• Patients treated with abatacept experienced fewer disease flares compared to placebo-treated patients (20% versus 53%, respectively, p<0.001)
• The risk of disease flare among patients continuing on abatacept was less than that for patients who withdrew from abatacept treatment (HR 0.31, 95% CI 0.16 to 0.59)
Please see the link above for further details.